WallStreetZenWallStreetZen

NASDAQ: PGEN
Precigen Inc Stock Forecast, Predictions & Price Target

Analyst price target for PGEN

Based on 3 analysts offering 12 month price targets for Precigen Inc.
Min Forecast
$4.00+392%
Avg Forecast
$7.00+761.01%
Max Forecast
$10.00+1,130.01%

Should I buy or sell PGEN stock?

Based on 3 analysts offering ratings for Precigen Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PGEN stock forecasts and price targets.

PGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-15
lockedlocked$00.00+00.00%2024-08-15
lockedlocked$00.00+00.00%2024-06-03

1 of 1

Forecast return on equity

Is PGEN forecast to generate an efficient return?
Company
140.52%
Industry
151.34%
Market
74.32%
PGEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PGEN forecast to generate an efficient return on assets?
Company
82.92%
Industry
25.73%
PGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PGEN earnings per share forecast

What is PGEN's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.44
Avg 2 year Forecast
-$0.19
Avg 3 year Forecast
$0.02

PGEN revenue forecast

What is PGEN's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$3.3M-25.81%
Avg 2 year Forecast
$20.6M+370.04%
Avg 3 year Forecast
$105.6M+2,305.1%
PGEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PGEN revenue growth forecast

How is PGEN forecast to perform vs Biotechnology companies and vs the US market?
Company
168.85%
Industry
37.85%
Market
9.43%
PGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PGEN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PGEN$0.81$7.00+761.01%Strong Buy
KOD$3.90$3.00-23.08%Hold
OBIO$5.46$16.33+199.14%Strong Buy
FULC$3.26$8.63+164.57%Buy
CYBN$10.12$50.50+399.01%Strong Buy

Precigen Stock Forecast FAQ

Is Precigen Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PGEN) stock is to Strong Buy PGEN stock.

Out of 3 analysts, 1 (33.33%) are recommending PGEN as a Strong Buy, 2 (66.67%) are recommending PGEN as a Buy, 0 (0%) are recommending PGEN as a Hold, 0 (0%) are recommending PGEN as a Sell, and 0 (0%) are recommending PGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Precigen stock.

What is PGEN's earnings growth forecast for 2024-2026?

(NASDAQ: PGEN) Precigen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.81%.

Precigen's earnings in 2024 is -$135,381,000.On average, 3 Wall Street analysts forecast PGEN's earnings for 2024 to be -$112,049,857, with the lowest PGEN earnings forecast at -$116,271,000, and the highest PGEN earnings forecast at -$108,688,108. On average, 3 Wall Street analysts forecast PGEN's earnings for 2025 to be -$48,024,978, with the lowest PGEN earnings forecast at -$50,552,609, and the highest PGEN earnings forecast at -$45,497,348.

In 2026, PGEN is forecast to generate $5,055,261 in earnings, with the lowest earnings forecast at $5,055,261 and the highest earnings forecast at $5,055,261.

What is PGEN's revenue growth forecast for 2024-2026?

(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 168.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.43%.

Precigen's revenue in 2024 is $4,389,000.On average, 3 Wall Street analysts forecast PGEN's revenue for 2024 to be $822,996,468, with the lowest PGEN revenue forecast at $449,918,217, and the highest PGEN revenue forecast at $1,213,262,606. On average, 2 Wall Street analysts forecast PGEN's revenue for 2025 to be $5,214,501,577, with the lowest PGEN revenue forecast at $824,007,520, and the highest PGEN revenue forecast at $9,604,995,634.

In 2026, PGEN is forecast to generate $26,681,666,819 in revenue, with the lowest revenue forecast at $26,681,666,819 and the highest revenue forecast at $26,681,666,819.

What is PGEN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PGEN) forecast ROA is 82.92%, which is higher than the forecast US Biotechnology industry average of 25.73%.

What is PGEN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PGEN price target, the average PGEN price target is $7.00, with the highest PGEN stock price forecast at $10.00 and the lowest PGEN stock price forecast at $4.00.

On average, Wall Street analysts predict that Precigen's share price could reach $7.00 by Aug 15, 2025. The average Precigen stock price prediction forecasts a potential upside of 761.01% from the current PGEN share price of $0.81.

What is PGEN's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: PGEN) Precigen's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that PGEN's EPS will be -$0.44 for 2024, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.43. On average, analysts forecast that PGEN's EPS will be -$0.19 for 2025, with the lowest EPS forecast at -$0.20, and the highest EPS forecast at -$0.18. In 2026, PGEN's EPS is forecast to hit $0.02 (min: $0.02, max: $0.02).

What is PGEN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PGEN) forecast ROE is 140.52%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.